Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorGIRAUD, Julie
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorCHALOPIN, Domitille
dc.contributor.authorBLANC, J.-F.
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorSALEH, Maya
dc.date.accessioned2022-05-04T08:33:24Z
dc.date.available2022-05-04T08:33:24Z
dc.date.issued2021-03-18
dc.identifier.issn1664-3224en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/139977
dc.description.abstractEnHepatocellular carcinoma (HCC) is the most common liver tumor and among the deadliest cancers worldwide. Advanced HCC overall survival is meager and has not improved over the last decade despite approval of several tyrosine kinase inhibitors (TKi) for first and second-line treatments. The recent approval of immune checkpoint inhibitors (ICI) has revolutionized HCC palliative care. Unfortunately, the majority of HCC patients fail to respond to these therapies. Here, we elaborate on the immune landscapes of the normal and cirrhotic livers and of the unique HCC tumor microenvironment. We describe the molecular and immunological classifications of HCC, discuss the role of specific immune cell subsets in this cancer, with a focus on myeloid cells and pathways in anti-tumor immunity, tumor promotion and immune evasion. We also describe the challenges and opportunities of immunotherapies in HCC and discuss new avenues based on harnessing the anti-tumor activity of myeloid, NK and ?? T cells, vaccines, chimeric antigen receptors (CAR)-T or -NK cells, oncolytic viruses, and combination therapies.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enCirrhosis
dc.subject.enImmune checkpoint inhibitors
dc.subject.enImmunosuppression
dc.subject.enImmunotherapy
dc.subject.enInflammation
dc.subject.enNASH
dc.subject.enTumor microenvironment
dc.subject.enTumor-associated macrophages
dc.title.enHepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
dc.typeArticle de revueen_US
dc.identifier.doi10.3389/fimmu.2021.655697en_US
dc.subject.halSciences du Vivant [q-bio]/Immunologieen_US
dc.identifier.pubmed33815418en_US
bordeaux.journalFrontiers in Immunologyen_US
bordeaux.volume12en_US
bordeaux.hal.laboratoriesImmunoConcEpT - UMR 5164en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDFondation ARC pour la Recherche sur le Canceren_US
bordeaux.identifier.funderIDConseil Régional Aquitaineen_US
hal.exportfalse
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers%20in%20Immunology&rft.date=2021-03-18&rft.volume=12&rft.eissn=1664-3224&rft.issn=1664-3224&rft.au=GIRAUD,%20Julie&CHALOPIN,%20Domitille&BLANC,%20J.-F.&SALEH,%20Maya&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée